COMPERA / COMPERA-KIDS

COMPERA will report current and comprehensive data on * Demographics and clinical course of incident and prevalent PAH and PH patients * Patient outcomes including survival, by subgroup, by treatment strategy and other factors * Clinical predictors of short-term and long-term clinical outcomes * Relationship between PAH medications and patient outcomes * Temporal trends in treatments and outcomes for newly diagnosed patients * The state of implementation of current PAH guidelines * Evolving research needs of the PAH community * Patients with PAH associated with congenital heart disease and Eisenmenger physiology who do not receive specific drug therapy for PAH ("COMPERA-Eisenmenger", as stated in the amendment dated 23. January 2012). * Children of any age with PH or PAH (all Dana Point groups), as stated in the amendment dated 1 June 2013 ("COMPERA-KIDS").